| Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA oncology 6 (5), 650-659, 2020 | 901 | 2020 |
| Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ... Journal of clinical oncology 40 (29), 3377-3382, 2022 | 126 | 2022 |
| The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited MP Deek, K Van der Eecken, R Phillips, NR Parikh, PI Velho, TL Lotan, ... European urology 80 (5), 632-640, 2021 | 86 | 2021 |
| Dosimetric predictors of symptomatic cardiac events after conventional-dose chemoradiation therapy for inoperable NSCLC N Yegya-Raman, K Wang, S Kim, M Reyhan, MP Deek, M Sayan, D Li, ... Journal of thoracic oncology 13 (10), 1508-1518, 2018 | 82 | 2018 |
| Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer MP Deek, K Taparra, R Phillips, PI Velho, RW Gao, C Deville, DY Song, ... European urology oncology 4 (3), 447-455, 2021 | 66 | 2021 |
| Thoracic vertebral body irradiation contributes to acute hematologic toxicity during chemoradiation therapy for non-small cell lung cancer MP Deek, B Benenati, S Kim, T Chen, I Ahmed, W Zou, J Aisner, ... International Journal of Radiation Oncology* Biology* Physics 94 (1), 147-154, 2016 | 56 | 2016 |
| Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience MP Deek, C Yu, R Phillips, DY Song, C Deville, S Greco, TL DeWeese, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 948-956, 2019 | 43 | 2019 |
| Tissue-and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review K Van der Eecken, J Vanwelkenhuyzen, MP Deek, PT Tran, E Warner, ... European Urology Oncology 4 (6), 914-923, 2021 | 33 | 2021 |
| Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment CL Moyer, R Phillips, MP Deek, N Radwan, AE Ross, ES Antonarakis, ... World journal of urology 37, 2623-2629, 2019 | 33 | 2019 |
| Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020; 6 (5): 650–9 R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis The ORIOLE trial found improvements in progression-free survival in patients …, 2020 | 32 | 2020 |
| Daily image guidance with cone beam computed tomography may reduce radiation pneumonitis in unresectable non-small cell lung cancer N Yegya-Raman, S Kim, MP Deek, D Li, A Gupta, L Bond, A Dwivedi, ... International Journal of Radiation Oncology* Biology* Physics 101 (5), 1104-1112, 2018 | 28 | 2018 |
| Smad4 loss correlates with higher rates of local and distant failure in pancreatic adenocarcinoma patients receiving adjuvant chemoradiation JM Herman, SK Jabbour, SH Lin, MP Deek, CC Hsu, EK Fishman, S Kim, ... Pancreas 47 (2), 208-212, 2018 | 27 | 2018 |
| Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer MP Deek, K Taparra, D Dao, L Chan, R Phillips, RW Gao, ED Kwon, ... International Journal of Radiation Oncology* Biology* Physics 109 (2), 387-395, 2021 | 26 | 2021 |
| A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS) H Hasan, MP Deek, R Phillips, RF Hobbs, R Malek, N Radwan, AP Kiess, ... BMC cancer 20, 1-13, 2020 | 26 | 2020 |
| Prognostic impact of missed chemotherapy doses during chemoradiation therapy for non–small cell lung cancer MP Deek, S Kim, I Ahmed, BS Fang, W Zou, J Malhotra, J Aisner, ... American journal of clinical oncology 41 (4), 362-366, 2018 | 24 | 2018 |
| Transcriptomic heterogeneity of Gleason grade group 5 prostate cancer AU Kishan, T Romero, M Alshalalfa, Y Liu, PT Tran, NG Nickols, H Ye, ... European urology 78 (3), 327-332, 2020 | 19 | 2020 |
| Oligometastatic and oligoprogression disease and local therapies in prostate cancer MP Deek, PT Tran The Cancer Journal 26 (2), 137-143, 2020 | 18 | 2020 |
| Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics P Sutera, K Van Der Eecken, AU Kishan, A Hamid, E Grist, G Attard, ... Prostate cancer and prostatic diseases 25 (4), 713-719, 2022 | 17 | 2022 |
| Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical … PT Tran, K Lowe, HL Tsai, DY Song, AY Hung, JWD Hearn, S Miller, ... Journal of Clinical Oncology 41 (6), 1307-1317, 2023 | 15 | 2023 |
| Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer P Sutera, Y Song, K Van der Eecken, AC Shetty, K English, T Hodges, ... European urology 84 (6), 531-535, 2023 | 12 | 2023 |